As the national debate over prescription drug prices and health care costs rages on, Matt Mowers, Republican candidate for NH-01, is trying to hide that he consulted for Mylan Pharmaceuticals and Tonix Pharmaceuticals.
As a candidate for federal office, Matt Mowers is required to make a personal finance disclosure so that New Hampshire voters are aware of his financial interests and potential conflicts of interest. Those disclosures can be filed electronically or by hand, however the latter is a tactic that can sometimes be used to conceal information from the public. During the primary, Mowers’s Republican opponent raised concerns about this lack of transparency and just this month an independent lawyer filed a complaint with the House Ethics committee and called for Mowers to re-file a legible disclosure.
“Matt Mowers’ decision to write in chicken scratch to cover up the fact that he is a consultant for Big Pharma companies while they were gouging Granite Staters is deceitful and dishonest,” said End Citizens United President Tiffany Muller. “It begs the question: what was he trying to hide? Matt Mowers should immediately come clean about his relationship with Big Pharma and his corporate clients. He owes it to New Hampshire families who have had to make unimaginable sacrifices to afford life-saving drugs because of Big Pharma’s greed.”
Matt Mowers’ personal financial disclosure:
[U.S. House of Representatives Clerk, Matthew Mowers PFD, 8/20/20]
Mylan Pharmaceuticals is the infamous company behind the skyrocketing cost of EpiPens. The company came under national scrutiny for increasing the cost of the life-saving pen from $103.50 in 2009 to $608.61 in 2016, even though it was approved by the FDA in 1987. Succumbing to public pressure, the pharma giant cut the price of pens in half in December 2016, but according to NPR “it still cost triple what the EpiPen had cost just a few years earlier.”
###